Patents by Inventor Isao Miyazaki

Isao Miyazaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10981920
    Abstract: The present invention provides a novel RET inhibitor comprising, as an active ingredient, a compound or a salt thereof that have not been known for their RET inhibitory activity, and also provides an agent for preventing or treating diseases (e.g., malignant tumors) that can be prevented or treated by RET inhibitory activity. The RET inhibitor comprises, as an active ingredient, a compound represented by Formula (I) below or a salts thereof: wherein A, R1 to R3, X, and n are as defined in the specification.
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: April 20, 2021
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Isao Miyazaki, Tadashi Shimamura, Masanori Kato, Hidenori Fujita
  • Patent number: 10807986
    Abstract: The problem to be solved by the present invention is to provide a novel compound having RET inhibitory activity. The present invention also provides a pharmaceutical preparation that is useful for the prevention and/or treatment of RET-related diseases, particularly cancer, based on RET inhibitory activity. The present invention provides a compound represented by Formula (I): wherein A, R2, and X are as defined in the specification; or a salt thereof.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: October 20, 2020
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Isao Miyazaki, Tadashi Shimamura, Masanori Kato, Hidenori Fujita, Satoru Iguchi
  • Patent number: 10787457
    Abstract: The present invention provides a novel RET inhibitor comprising, as an active ingredient, a compound or a salt thereof that have not been known for their RET inhibitory activity, and also provides an agent for preventing or treating diseases (e.g., malignant tumors) that can be prevented or treated by RET inhibitory activity. The RET inhibitor comprises, as an active ingredient, a compound represented by Formula (I) below or a salts thereof: wherein A, R1 to R3, X, and n are as defined in the specification.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: September 29, 2020
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Isao Miyazaki, Tadashi Shimamura, Masanori Kato, Hidenori Fujita
  • Publication number: 20200270260
    Abstract: The present invention provides a novel RET inhibitor comprising, as an active ingredient, a compound or a salt thereof that have not been known for their RET inhibitory activity, and also provides an agent for preventing or treating diseases (e.g., malignant tumors) that can be prevented or treated by RET inhibitory activity. The RET inhibitor comprises, as an active ingredient, a compound represented by Formula (I) below or a salts thereof: wherein A, R1 to R3, X, and n are as defined in the specification.
    Type: Application
    Filed: April 22, 2020
    Publication date: August 27, 2020
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Isao MIYAZAKI, Tadashi SHIMAMURA, Masanori KATO, Hidenori FUJITA
  • Publication number: 20200270261
    Abstract: The present invention provides a novel RET inhibitor comprising, as an active ingredient, a compound or a salt thereof that have not been known for their RET inhibitory activity, and also provides an agent for preventing or treating diseases (e.g., malignant tumors) that can be prevented or treated by RET inhibitory activity. The RET inhibitor comprises, as an active ingredient, a compound represented by Formula (I) below or a salts thereof: wherein A, R1 to R3, X, and n are as defined in the specification.
    Type: Application
    Filed: April 22, 2020
    Publication date: August 27, 2020
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Isao MIYAZAKI, Tadashi SHIMAMURA, Masanori KATO, Hidenori FUJITA
  • Publication number: 20200270253
    Abstract: The problem to be solved by the present invention is to provide a novel compound having RET inhibitory activity. The present invention also provides a pharmaceutical preparation that is useful for the prevention and/or treatment of RET-related diseases, particularly cancer, based on RET inhibitory activity. The present invention provides a compound represented by Formula (I): wherein A, R2, and X are as defined in the specification; or a salt thereof.
    Type: Application
    Filed: May 13, 2020
    Publication date: August 27, 2020
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Isao MIYAZAKI, Tadashi SHIMAMURA, Masanori KATO, Hidenori FUJITA, Satoru IGUCHI
  • Publication number: 20190330214
    Abstract: The problem to be solved by the present invention is to provide a novel compound having RET inhibitory activity. The present invention also provides a pharmaceutical preparation that is useful for the prevention and/or treatment of RET-related diseases, particularly cancer, based on RET inhibitory activity. The present invention provides a compound represented by Formula (I): wherein A, R2, and X are as defined in the specification; or a salt thereof.
    Type: Application
    Filed: November 1, 2018
    Publication date: October 31, 2019
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Isao MIYAZAKI, Tadashi SHIMAMURA, Masanori KATO, Hidenori FUJITA, Satoru IGUCHI
  • Publication number: 20190092776
    Abstract: The present invention provides a novel RET inhibitor comprising, as an active ingredient, a compound or a salt thereof that have not been known for their RET inhibitory activity, and also provides an agent for preventing or treating diseases (e.g., malignant tumors) that can be prevented or treated by RET inhibitory activity. The RET inhibitor comprises, as an active ingredient, a compound represented by Formula (I) below or a salts thereof: wherein A, R1 to R3, X, and n are as defined in the specification.
    Type: Application
    Filed: November 29, 2018
    Publication date: March 28, 2019
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Isao MIYAZAKI, Tadashi SHIMAMURA, Masanori KATO, Hidenori FUJITA
  • Patent number: 10233189
    Abstract: The present invention provides a novel RET inhibitor comprising, as an active ingredient, a compound or a salt thereof that have not been known for their RET inhibitory activity, and also provides an agent for preventing or treating diseases (e.g., malignant tumors) that can be prevented or treated by RET inhibitory activity. The RET inhibitor comprises, as an active ingredient, a compound represented by Formula (I) below or a salts thereof: wherein A, R1 to R3, X, and n are as defined in the specification.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: March 19, 2019
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Isao Miyazaki, Tadashi Shimamura, Masanori Kato, Hidenori Fujita
  • Patent number: 10179788
    Abstract: The present invention provides a novel RET inhibitor comprising, as an active ingredient, a compound or a salt thereof that have not been known for their RET inhibitory activity, and also provides an agent for preventing or treating diseases (e.g., malignant tumors) that can be prevented or treated by RET inhibitory activity. The RET inhibitor comprises, as an active ingredient, a compound represented by Formula (I) below or a salts thereof: wherein A, R1 to R3, X, and n are as defined in the specification.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: January 15, 2019
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Isao Miyazaki, Tadashi Shimamura, Masanori Kato, Hidenori Fujita
  • Patent number: 10155768
    Abstract: The problem to be solved by the present invention is to provide a novel compound having RET inhibitory activity. The present invention also provides a pharmaceutical preparation that is useful for the prevention and/or treatment of RET-related diseases, particularly cancer, based on RET inhibitory activity. The present invention provides a compound represented by Formula (I): wherein A, R2, and X are as defined in the specification; or a salt thereof.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: December 18, 2018
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Isao Miyazaki, Tadashi Shimamura, Masanori Kato, Hidenori Fujita, Satoru Iguchi
  • Publication number: 20180009817
    Abstract: The present invention provides a novel RET inhibitor comprising, as an active ingredient, a compound or a salt thereof that have not been known for their RET inhibitory activity, and also provides an agent for preventing or treating diseases (e.g., malignant tumors) that can be prevented or treated by RET inhibitory activity. The RET inhibitor comprises, as an active ingredient, a compound represented by Formula (I) below or a salts thereof: wherein A, R1 to R3, X, and n are as defined in the specification.
    Type: Application
    Filed: September 11, 2017
    Publication date: January 11, 2018
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Isao MIYAZAKI, Tadashi SHIMAMURA, Masanori KATO, Hidenori FUJITA
  • Publication number: 20180009818
    Abstract: The problem to be solved by the present invention is to provide a novel compound having RET inhibitory activity. The present invention also provides a pharmaceutical preparation that is useful for the prevention and/or treatment of RET-related diseases, particularly cancer, based on RET inhibitory activity. The present invention provides a compound represented by Formula (I): wherein A, R2, and X are as defined in the specification; or a salt thereof.
    Type: Application
    Filed: September 19, 2017
    Publication date: January 11, 2018
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Isao MIYAZAKI, Tadashi SHIMAMURA, Masanori KATO, Hidenori FUJITA, Satoru IGUCHI
  • Patent number: 7304001
    Abstract: Under the condition that a semiconductor maker and a photomask maker are separated but these are mutually connected with a communication line, the semiconductor maker gives a photomask fabrication schedule information to the photomask maker via the communication line, while the photomask maker fabricates the photomask depending on such fabrication schedule information and delivers the photomask to the semiconductor maker. The photomask maker periodically sends, in the course of fabrication process, a photomask fabrication progress information to the semiconductor maker via the communication line. The semiconductor maker regenerates the photomask fabrication schedule information depending on the photomask fabrication progress information sent from the photomask maker and then transfers the re-generated photomask fabrication schedule information to the photomask maker via the communication line.
    Type: Grant
    Filed: August 21, 2002
    Date of Patent: December 4, 2007
    Assignee: Renesas Technology Corp.
    Inventors: Isao Miyazaki, Yasushi Takeuchi, Toshihiro Morii, Koji Sekiguchi, Yoshihiko Okamoto
  • Publication number: 20070248951
    Abstract: Disclosed herein are a determination method capable of determining the presence or absence of an anti-HIV antibody in a sample with accuracy even if an operation of cleaning is omitted and a determination kit to be used for the determination method. The determination method is as follows. First, a liquid specimen containing a sample obtained from a living body is fed into a well carrying a HIV antigen on an inner surface thereof. Next, a reagent containing colored particles carrying an anti-IgG antibody is fed into the well. Then in a case where the anti-IgG antibody is bound to the anti-HIV antibody which has been bound to the HIV antigen so that the particles are dispersed in the well, the sample is positive, while that in a case where the particles are precipitated and agglutinated in the well, the sample is negative.
    Type: Application
    Filed: October 19, 2006
    Publication date: October 25, 2007
    Applicant: PENTAX Corporation
    Inventors: Kazumi YAGASAKI, Isao MIYAZAKI
  • Publication number: 20070141596
    Abstract: Disclosed herein are a plate capable of determining the presence or absence of an anti-virus antibody with higher accuracy, a determination kit equipped with the plate, and a determination method using the determination kit for immunoassay. The determination method is as follows. First, a liquid specimen is fed into each of the predetermined wells of the plate fixed two or more kinds of antigens derived from a specific virus. Each well carries one of the two or more kinds of antigens on the inner surface thereof. Then, a reagent containing colored particles 1 carrying an anti-IgG antibody is fed into each of the wells containing the liquid specimen. When an antibody bound to the antigen is detected in a predetermined number or more of the wells, a living body is determined to be infected with the virus.
    Type: Application
    Filed: October 19, 2006
    Publication date: June 21, 2007
    Applicant: PENTAX CORPORATION
    Inventors: Kazumi Yagasaki, Isao Miyazaki
  • Patent number: 7052842
    Abstract: A method for hybridizing nucleic acids, which includes an annealing step of preparing a first single stranded nucleic acid fragment immobilized on a surface of an immobilizing material and a second single stranded nucleic acid fragment labeled with fluorescence or radioisotope and forming a complementary double strand from the first single stranded nucleic acid fragment and the second single stranded nucleic acid fragment, and an enzyme treatment step. In the annealing step, the complementary double strand is formed by performing a temperature gradient processing performed from a high temperature area to a low temperature area, and in the enzyme treatment step, a noncomplementary nucleic acid portion contained in the complementary double stand is recognized and cleaved by adding endonuclease. This method has high measurement sensitivity and the operation is simple.
    Type: Grant
    Filed: March 1, 2002
    Date of Patent: May 30, 2006
    Assignee: NGK Insulators, Ltd.
    Inventors: Mitsuo Kawase, Kazunari Yamada, Isao Miyazaki, Chiho Matsuda
  • Patent number: 6757621
    Abstract: A process management system in accordance with the present invention includes inspection apparatuses for inspecting defects on a wafer, the inspection apparatuses being connected through a communication network, inspection information and image information obtained from these inspection apparatuses being collected to construct a data base and an image file, therein definition of defects is given by combinations of elements which characterize the defect based on the inspection information and the image information obtained from the inspection apparatuses. By giving definition of the defect, characteristics of the defect can be subdivided and known. Therefore, the cause of a defect can be studied.
    Type: Grant
    Filed: January 16, 2003
    Date of Patent: June 29, 2004
    Assignees: Hitachi, Ltd., Hitachi Engineering Co., Ltd.
    Inventors: Fumio Mizuno, Seiji Isogai, Kenji Watanabe, Yasuhiro Yoshitake, Terushige Asakawa, Yuichi Ohyama, Hidekuni Sugimoto, Seiji Ishikawa, Masataka Shiba, Jun Nakazato, Makoto Ariga, Tetsuji Yokouchi, Toshimitsu Hamada, Ikuo Suzuki, Masami Ikota, Mari Nozoe, Isao Miyazaki, Yoshiharu Shigyo
  • Publication number: 20030186266
    Abstract: A method for hybridizing nucleic acids, which includes an annealing step of preparing a first single stranded nucleic acid fragment immobilized on a surface of an immobilizing material and a second single stranded nucleic acid fragment labeled with fluorescence or radioisotope and forming a complementary double strand from the first single stranded nucleic acid fragment and the second single stranded nucleic acid fragment, and an enzyme treatment step. In the annealing step, the complementary double strand is formed by performing a temperature gradient processing performed from a high temperature area to a low temperature area, and in the enzyme treatment step, a noncomplementary nucleic acid portion contained in the complementary double stand is recognized and cleaved by adding endonuclease. This method has high measurement sensitivity and the operation is simple.
    Type: Application
    Filed: October 23, 2002
    Publication date: October 2, 2003
    Inventors: Mituso Kawase, Kazunari Yamada, Isao Miyazaki, Chiho Matsuda
  • Patent number: 6628817
    Abstract: The present invention provides data analysis stations respectively for a probing tester and an automatic particle inspection machine. And, in the data analysis station, the coordinates on which the disposition of the chips are described on a product basis are equal to those on which the locations of the defects are described. Further, the station provides a function of determining which of the chips each defect belongs to. These data analysis stations are connected through a communication line. The present invention is capable of analyzing the data on a chip basis, resulting in being able to grasp the relation between how the defects are caused on each chip and the product character of the chip.
    Type: Grant
    Filed: January 3, 2001
    Date of Patent: September 30, 2003
    Assignee: Hitachi, Ltd.
    Inventors: Seiji Ishikawa, Masao Sakata, Jun Nakazato, Sadao Shimoyashiro, Hiroto Nagatomo, Yuzo Taniguchi, Osamu Satou, Tsutomu Okabe, Yuzaburo Sakamoto, Kimio Muramatsu, Kazuhiko Matsuoka, Taizo Hashimoto, Yuichi Ohyama, Yutaka Ebara, Isao Miyazaki, Shuichi Hanashima